Eli Lilly's Alzheimer's Drug Obtains FDA Approval. Here's Why the Stock Isn't Taking Off.
Eli Lilly (NYSE: LLY) received some great news from regulators last week: Its Alzheimer's treatment obtained the green light from the Food and Drug Administration (FDA). The new drug, Kisunla, has the potential to be a blockbuster for the company and …